Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Apr, 4 2026
Dec, 7 2024
Sep, 6 2024
May, 18 2026
Aug, 21 2025